Abstract: A learning unit of a learning system generates the following learning model. That is, this learning model is a model that inputs rehabilitation data for each predetermined period and predicts a change in index data, the rehabilitation data being data about rehabilitation performed by a trainee using a rehabilitation support system, the index data indicating at least one of a symptom, a physical ability, and a degree of recovery of the trainee. This rehabilitation data includes at least the index data and training data of the trainee, the training data being acquired during the rehabilitation in the rehabilitation support system. Further, the learning unit generates the learning model by using, as teacher data, data obtained in a period until the index data reaches a predetermined target level.

Abstract: A control system includes a communication control device including a memory, and a processor coupled to the memory and configured to execute a determination process that includes, when an operation request is received via a specific destination server, determining whether the operation request is a management operation or an application operation based on header information included in the operation request, execute a transfer process that includes, if the operation request is the application operation, transferring the operation request related to the application operation to a server running the application, and execute a blocking process that includes, if the operation request is the management operation, blocking the operation request related to the management operation.

Abstract: It is intended to provide a drug which is efficacious in treating and preventing diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof. Because of containing as the active ingredient a substance selected from among farnesol, a farnesol derivative, a tocopherol derivative, a tocotrienol derivative, pharmacologically acceptable salts thereof and solvates thereof, the above-described inhibitor of ischemic disorders can exert therapeutic and preventive effects on diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof (for example, brain infarction, brain edema, cardiac infarction, etc.) not only by the administration in the acute ischemic stage but also by the therapeutic administration in subacute and/or chronic stages after ischemia-reperfusion. It is also intended to provide a farnesol carboxylic acid ester derivative and a method of producing the same.

Abstract: An object of the present invention is to provide dermatological agents such as whitening agents and hair growth accelerators that contain a compound having high water solubility and a specific structure capable of releasing 2,3-dimethoxy-5-methyl-1,4-dihydroxybenzene (reduced form). A dermatological agent according to the present invention contains a 2,3-dimethoxy-5-methyl-1,4-dihydroxybenzenecarboxylic acid ester derivative represented by the following general Formula (I) or a salt thereof: wherein in the Formula (I), R1, R2 and R3 are specific groups.

Abstract: It is intended to provide a drug which is efficacious in treating and preventing diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof. Because of containing as the active ingredient a substance selected from among farnesol, a farnesol derivative, a tocopherol derivative, a tocotrienol derivative, pharmacologically acceptable salts thereof and solvates thereof, the above-described inhibitor of ischemic disorders can exert therapeutic and preventive effects on diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof (for example, brain infarction, brain edema, cardiac infarction, etc.) not only by the administration in the acute ischemic stage but also by the therapeutic administration in subacute and/or chronic stages after ischemia-reperfusion. It is also intended to provide a farnesol carboxylic acid ester derivative and a method of producing the same.

Abstract: A multiple-processor information processing system is capable of reducing adverse influence of overload of a given communication process on other communication processes. In this multiple-processor information processing system, a virtual IP address definition section defines virtual IP addresses on a process module-by-processor module basis. A storage device stores the virtual IP addresses defined by the virtual IP address definition section and information indicative of ones of the processor modules corresponding to the virtual IP addresses, respectively, in a state correlated with each other. A notification section notifies a router of a virtual IP address of each processor module and a real IP address of the each process module as routing information, for each processor module having the virtual IP address stored in the storage device.

Abstract: RCAS1 in a specimen is measured by a immunologically method consisting of a step of reacting a specimen with a first anti-RCAS1 antibody capable of specifically binding to RCAS1, a step of labeling the first reaction product produced by the aforementioned step, and a step of measuring a labeled amount of the labeled first reaction product. As RCAS1, recombinant RCAS1 is used. In addition, as a first anti-RCAS1, a monoclonal antibody derived from the SiSo cell line is used.

Abstract: A front-end processor and a routing management method capable of appropriately controlling the loads on respective routing paths. An Allocating section allocates a router on a first network to a routing section, and a routing information transmitting section transmits routing information to the router allocated to the routing section. The router, which is thus supplied with the routing information, accesses a server computer via the routing section, whereby the processing load of the routing section can be appropriately controlled.

Abstract: RCAS1 in a specimen is measured by a immunoglogically method consisting of a step of reacting a specimen with a first anti-RCAS1 antibody capable of specifically binding to RCAS1, a step of labeling the first reaction product produced by the aforementioned step, and a step of measuring a labeled amount of the labeled first reaction product. As RCAS1, recombinant RCAS1 is used. In addition, as a first anti-RCAS1, a monoclonal antibody derived from the SiSo cell line is used.

Abstract: There is provided a multiple-processor information processing system which is capable of reducing adverse influence of overload of a given communication process on other communication processes than the given communication process. In this multiple-processor information processing system, a virtual IP address definition section defines virtual IP addresses on a process module-by-processor module basis. A storage device stores the virtual IP addresses defined by the virtual IP address definition section and information indicative of ones of the processor modules corresponding to the virtual IP addresses, respectively, in a state correlated with each other. A notification section notifies a router of a virtual IP address of each processor module and a real IP address of the each process module as routing information, for the each processor module having the virtual IP address stored in the storage device.